The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: Simulations from a pharmacokinetic-pharmacodynamic model

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 6, 2011, Pages 494-498

  Wright, Daniel F B ^a   Pavan Kumar, Venkata V ^a   Al Sallami, Hesham S ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ARTICLE; BEDTIME DOSAGE; BIOEQUIVALENCE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICHOLESTEREMIC AGENTS; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; SIMVASTATIN; THERAPEUTIC EQUIVALENCY;

EID: 81255157882     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00757.x     Document Type: Article

References (28)

1. Law M, Wald N, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Br Med J 1994;308:363-6.
2. Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard WJ et al. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-97.
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
4. Miida T, Nakamura Y, Mezaki T, Hanyu O, Maruyama S, Horikawa Y et al. LDL-cholesterol and HDL-cholesterol concentrations decrease during the day. Ann Clin Biochem 2002;39:241-9.
5. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH Jr, Alberts AW et al. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984;74:795-804.
6. Lund TM, Torsvik H, Falch D, Christophersen B, Skardal R, Gullestad L. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol 2002;90:784-6.
7. Anon. Cholesterol fairy home to roost. Bandolier 2001;8:7-8.
8. Illingworth DR. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 1986;40:338-43.
9. Shepherd G. Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. Eur Heart J 2003;24:685-9.
10. Kim J, Ahn B-J, Chae H-S, Han S, Doh K, Lee J et al. A population pharmacokinetic and pharmacodynamic approach of simvastatin in healthy volunteers. Population Approach Group of Australia and New Zealand Annual Conference; Adelaide, SA Feb 8-10 2010.
11. Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P et al. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 2006;20:321-30.
12. Mengden T, Binswanger B, Spuhler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993;11:1403-11.
13. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60.
14. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J 2008;336:1114-7.
15. Mallion JM, Meilhac B, Tremel F, Calvez R, Bertholom N. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol 1992;19(Suppl 2):S41-8.
16. Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993;45:211-5.
17. Kim J, Ahn B-J, Chae H-S, Han S, Doh K, Lee J et al. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts LDL-cholesterol reduction in patients with primary hyperlipidemia. Basic Clin Pharmacol Toxicol 2011 (in press) DOI:.
18. Idkaidek NM, Najib NM, Arafat T, Al-Ghazawi A. Population pharmacokinetics of atorvastatin, simvastatin and pravastatin after oral administration in humans. Saudi Pharm J 2008;16: 82-4.
19. Jones PJH, Pappu AS, Illingworth DR, Leitch CA. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur J Clin Invest 1992;22:609-13.
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
21. Merck. ZOCOR (simvastatin) package insert. [cited April 20, 2011].
22. Yoshida H, Ishikawa T, Ayaori M, Shige H, Hosoai H, Nishio E et al. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. Clin Ther 1995;17:379-89.
23. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
24. Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43-50.
25. US FDA. Statistical Approaches to Establishing Bioequivalence. Rockville MD2001 [cited January 29, 2011].
26. Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga REB, Nucci GD et al. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos 2003;24:183-9.
27. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11:816-26.
28. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. Br Med J 2003;327:788.